scholarly journals Burden of Respiratory Syncytial Virus Infection During the First Year of Life

2020 ◽  
Author(s):  
Emilia Thomas ◽  
Janna-Maija Mattila ◽  
Pasi Lehtinen ◽  
Tytti Vuorinen ◽  
Matti Waris ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Incidence Rate ◽  
Otitis Media ◽  
Acute Otitis Media ◽  
Respiratory Illness ◽  
First Year ◽  
Seasonal Incidence ◽  
Rsv Infection ◽  
Syncytial Virus ◽  
First Year Of Life

Abstract Background Although many infants with respiratory syncytial virus (RSV) infection are hospitalized, most infants are treated as outpatients. Limited data are available on the burden of RSV in outpatient infants. Methods In a prospective study, we enrolled 431 newborn infants and followed them for a 10-month period (September-June). During each respiratory illness, we examined the infants and obtained nasopharyngeal specimens for the detection of RSV. The parents completed daily symptom diaries throughout the study. Results Among 408 active participants, the seasonal incidence rate of RSV illness was 328.4 per 1000 (95% confidence interval [CI] 275.2-389.0). Infants with ≥1 sibling had a 1.9-fold higher incidence of RSV illness than those without (95% CI 1.3-2.8; P = .0007). Acute otitis media developed in 103 (76.9%) of 134 infants with RSV infection, and 95 (70.9%) were treated with antibiotics. Nine (6.7%) infants with RSV were hospitalized, for a seasonal incidence rate of RSV hospitalization of 22.1 per 1000 (95% CI 10.1-41.9). Conclusions The outpatient burden of RSV is heavy on infants during the first year of life. Acute otitis media is a frequent complication of RSV, and it should be included in cost-effectiveness analyses of prevention or treatment of RSV infections in infants.

scholarly journals Genomewide Association Analysis of Respiratory Syncytial Virus Infection in Mice

2009 ◽  
Vol 84 (5) ◽  
pp. 2257-2269 ◽  
Author(s):  
James M. Stark ◽  
M. Michael Barmada ◽  
Abby V. Winterberg ◽  
Nilanjana Majumber ◽  
William J. Gibbons ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Syncytial Virus ◽  
Respiratory Morbidity ◽  
First Year ◽  
Transmembrane Conductance Regulator ◽  
Rsv Infection ◽  
Proximal Mouse ◽  
Trait Locus ◽  
Syncytial Virus ◽  
First Year Of Life

ABSTRACT Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants, with about half being infected in their first year of life. Yet only 2 to 3% of infants are hospitalized for RSV infection, suggesting that individual susceptibility contributes to disease severity. Previously, we determined that AKR/J (susceptible) mice developed high lung RSV titers and showed delayed weight recovery, whereas C57BL/6J (resistant) mice demonstrated low lung RSV titers and rapid weight recovery. In addition, we have reported that gene-targeted mice lacking the cystic fibrosis transmembrane conductance regulator (Cftr; ATP-binding cassette subfamily C, member 7) are susceptible to RSV infection. For this report, recombinant backcross and F2 progeny derived from C57BL/6J and AKR/J mice were infected with RSV, their lung titers were measured, and quantitative trait locus (QTL) analysis was performed. A major QTL, designated Rsvs1, was identified on proximal mouse chromosome 6 in both recombinant populations. Microarray analysis comparing lung transcripts of the parental strains during infection identified several candidate genes that mapped to the Rsvs1 interval, including Cftr. These findings add to our understanding of individual RSV susceptibility and strongly support a modifier role for CFTR in RSV infection, a significant cause of respiratory morbidity in infants with cystic fibrosis.

scholarly journals Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada

2021 ◽  
Author(s):  
Ian Mitchell ◽  
Abby Li ◽  
Candice L. Bjornson ◽  
Krista L. Lanctot ◽  
Bosco A. Paes ◽  
...  
Keyword(s):  
Risk Factors ◽  
Respiratory Syncytial Virus ◽  
Burden Of Illness ◽  
Respiratory Illness ◽  
Smoking Exposure ◽  
Key Points ◽  
Rsv Infection ◽  
History Of ◽  
Syncytial Virus ◽  
Airway Anomalies

Objective This study aimed to evaluate palivizumab (PVZ) use, trends in indications, and outcomes of respiratory illness hospitalizations (RIH) and respiratory syncytial virus hospitalizations (RSVH). Study Design It involves a large, Canadian prospective (2005–2017) observational multicenter study of children at high risk for RSV infection. Results A total of 25,003 infants (56.3% male) were enrolled at 32 sites; 109,579 PVZ injections were administered. Indications included: prematurity (63.3%); “miscellaneous” (17.8%); hemodynamically significant congenital heart disease (10.5%); bronchopulmonary dysplasia/chronic lung disease (8.4%). The “miscellaneous” group increased over time (4.4% in 2005–2006 to 22.5% in 2016–2017) and included: trisomy 21, airway anomalies, pulmonary disorders, cystic fibrosis, neurological impairments, immunocompromised, cardiac aged >2 years, multiple conditions, and a residual “unclassified” group. Adherence measured by expected versus actual doses plus correct interdose interval was 64.7%. A total of 2,054 RIH occurred (6.9%); 198 (9.6%) required intubation. Three hundred thirty-seven hospitalized children were RSV-positive (overall RSVH 1.6%). Risk factors for RSVH included having siblings, attending daycare, family history of atopy, smoking exposure, and crowded household. Infants with 5 risk factors were 9.0 times (95% CI or confidence interval 4.4–18.2; p < 0.0005) more likely to have RSVH than infants without risk factors. Three adverse events occurred; none were fatal. Conclusion Results are relevant to both clinicians and decision-makers. We confirmed the safety of PVZ. Use of PVZ increased steadily for children with miscellaneous conditions and medical complexity. Medical and social factors pose a risk for severe RIH and RSVH with accompanying burden of illness. A vaccine that protects against RSV is urgently required. Key Points

scholarly journals Respiratory Syncytial Virus Epidemiology in a Birth Cohort from Kilifi District, Kenya: Infection during the First Year of Life

2004 ◽  
Vol 190 (10) ◽  
pp. 1828-1832 ◽  
Author(s):  
D. James Nokes ◽  
Emelda A. Okiro ◽  
Mwanajuma Ngama ◽  
Lisa J. White ◽  
Rachel Ochola ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Birth Cohort ◽  
First Year ◽  
Syncytial Virus ◽  
First Year Of Life

Detection of Genomic Sequences of Respiratory Syncytial Virus in Otitis Media with Effusion in Children

1992 ◽  
Vol 101 (10_suppl) ◽  
pp. 7-10 ◽  
Author(s):  
Yoshitaka Okamoto ◽  
Kazuo Kudo ◽  
Koji Shirotori ◽  
Misao Nakazawa ◽  
Eiko Ito ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Respiratory Syncytial Virus ◽  
Otitis Media ◽  
Otitis Media With Effusion ◽  
Chain Reaction ◽  
Nested Polymerase Chain Reaction ◽  
Rsv Infection ◽  
Polymerase Chain ◽  
Syncytial Virus ◽  
Viral Sequences

The reverse transcriptase—polymerase chain reaction and the nested polymerase chain reaction were used for detection of respiratory syncytial virus (RSV) sequences in middle ear effusions collected from children with otitis media. Sequences of RSV were detected in 21 of 34 samples tested. These samples were collected during and/or after natural outbreaks of RSV infection in the community. In those patients from whose nasopharynges RSV was isolated, the viral sequences were highly detectable (75%) in the effusions. These observations suggest RSV as an important factor in the pathogenesis of otitis media with effusion.

scholarly journals 749. Healthcare Utilization After Hospitalization for Respiratory Syncytial Virus or Unspecified Bronchiolitis in the First Year of Life

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S268-S269
Author(s):  
Joel Ledbetter ◽  
Lance Brannman ◽  
Sally Wade ◽  
David Diakun ◽  
Tara Gonzales ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Healthcare Utilization ◽  
Healthcare Resource Utilization ◽  
Urgent Care ◽  
First Year ◽  
Chi Squared ◽  
Ed Visits ◽  
Syncytial Virus ◽  
First Year Of Life

Abstract Background Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations and risk varies by gestational age (GA). Healthcare utilization following early hospitalizations caused by RSV (RSVH) or unspecified bronchiolitis (UBH) is not well understood. This study examined healthcare resource utilization (HRU) across GA categories within 12 months after an initial RSVH or UBH occurring in the first year of life. Methods Infants born July 1, 2009 to June 30, 2015 were identified in the MarketScan Commercial (COM) and Multistate Medicaid (MED) databases and assigned to GA categories using DRG and ICD codes and to an initial hospitalization cohort using inpatient claim diagnosis codes (RSVH, UBH without RSVH, or COMP [a comparator without RSVH or UBH]). Index dates (first admission dates for hospitalized infants) were assigned to COMP infants using times from birth to index dates among RSVH infants. HRU (hospitalizations, outpatient pharmacy fills, and visits for emergency department [ED], urgent care, wellness, other office or outpatient) excluded index hospitalizations and was assessed from 14 days post-index (or discharge if later) through 12 months post-index. Results were propensity score weighted to balance pre-index characteristics (age, sex, region, GA, birth hospitalization characteristics) across cohorts. Proportions were compared with chi-squared tests. Results Among all infants (all GA categories combined), the proportions of RSVH and UBH cohorts with follow-up hospitalizations or ED visits were greater (P &lt; 0.05) than COMP (hospitalizations: COM +5.8%, +9.3%; MED +9.1%, +12.0%; ED visits: COM +15.8%, +16.2%; MED +14.4%, +17.1%). Follow-up hospitalizations in COM and MED and ED visits in COM declined with greater GA (Figures 1 and 2). HRU in other categories (fills, visits) was significantly (P &lt; 0.05) greater among RSVH or UBH infants relative to COMP for nearly all GA categories in both COM and MED. Conclusion Infants hospitalized for RSV or UB in their first year of life had greater use of inpatient and outpatient resources in the 12 months following their initial hospitalizations compared with nonhospitalized infants. Inpatient care during follow-up was greatest among infants born at earlier GA. Funded by AstraZeneca Disclosures J. Ledbetter, AstraZeneca: Speaker’s Bureau, Speaker honorarium. L. Brannman, AstraZeneca: Employee, Salary and Stocks. S. Wade, Wade Outcomes Research and Consulting: Employee, Salary. D. Diakun, Truven Health Analytics, an IBM Company: Employee, Salary. T. Gonzales, AstraZeneca: Employee, Salary and Stocks. A. Kong, Truven Health Analytics, an IBM Company: Employee, Salary.

scholarly journals Symptomatic and Asymptomatic Respiratory Viral Infections in the First Year of Life: Association With Acute Otitis Media Development

2014 ◽  
Vol 60 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Tasnee Chonmaitree ◽  
Pedro Alvarez-Fernandez ◽  
Kristofer Jennings ◽  
Rocio Trujillo ◽  
Tal Marom ◽  
...  
Keyword(s):  
Otitis Media ◽  
Viral Infections ◽  
Acute Otitis Media ◽  
First Year ◽  
Media Development ◽  
Respiratory Viral Infections ◽  
First Year Of Life

The Effect of Birth Month on the Risk of Respiratory Syncytial Virus Hospitalization in the First Year of Life in the United States

2014 ◽  
Vol 33 (6) ◽  
pp. e135-e140 ◽  
Author(s):  
Patricia Calderón Lloyd ◽  
Larissa May ◽  
Daniel Hoffman ◽  
Richard Riegelman ◽  
Lone Simonsen
Keyword(s):  
United States ◽  
Respiratory Syncytial Virus ◽  
The United States ◽  
First Year ◽  
Birth Month ◽  
Syncytial Virus ◽  
First Year Of Life

Infection by the respiratory syncytial virus in infants and young children at high risk

2005 ◽  
Vol 15 (3) ◽  
pp. 256-265 ◽  
Author(s):  
Damien Bonnet ◽  
Achim A. Schmaltz ◽  
Timothy F. Feltes
Keyword(s):  
Respiratory Syncytial Virus ◽  
High Risk ◽  
Respiratory Tract ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Lower Respiratory Tract ◽  
First Year ◽  
Syncytial Virus ◽  
First Year Of Life ◽  
Infants And Young Children

The respiratory syncytial virus is the most common cause of infection of the lower respiratory tract in infants and young children, and is the leading cause of hospitalisation and death due to viral illness during the first year of life. In otherwise healthy infants, the virus usually causes only mild respiratory illness, but premature babies and infants with chronic lung disease, those with congenitally malformed hearts, or those who are immunodeficient, are at increased risk of serious illness, hospitalisation, and death. Recent infection with the virus is also associated with increased postoperative complications after corrective surgery for congenitally malformed hearts. No effective vaccine is currently available, and treatment is limited to supportive therapy. Prevention in groups deemed to be at high-risk, therefore, is essential. In addition to measures for control of infection, prophylactic immunotherapy is indicated in selected patients. Palivizumab (Synagis®) is a monoclonal antibody indicated for the prevention of serious viral disease of the lower respiratory tract in premature infants, those with chronic lung disease, and those with haemodynamically significant congenital cardiac lesions. Palivizumab is given intramuscularly, usually as a monthly injection during the so-called “season”. In a recent international, randomised, double-blind, placebo-controlled trial in 1,287 children less than or equal to 2 years old with haemodynamically significant congenital cardiac malformations, prophylaxis achieved a relative reduction of 45 per cent in the incidence of antigen-confirmed viral-related hospitalisation, and reduced the duration of hospital stay by 56 per cent. National and international guidelines, therefore, now recommend routine prophylaxis in the first year of life in children with haemodynamically significant congenital cardiac disease.

Sign in / Sign up

Export Citation Format

Share Document